How to Buy Sarepta Therapeutics Stock
Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
Sarepta Therapeutics stock last closed at $53.79, down 0.28% from the previous day, and has decreased 54.37% in one year. It has overperformed other stocks in the Biotechnology industry by 0.24 percentage points. Sarepta Therapeutics stock is currently +12.04% from its 52-week low of $48.01, and -68.95% from its 52-week high of $173.25.
There are currently 97.03M SRPT shares outstanding. The market cap of SRPT is $5.22B. In the last 24 hours, 1.91M SRPT shares were traded.
How to Buy Sarepta Therapeutics Stock
Wondering how to invest in Sarepta Therapeutics stock? Here's how.
- Decide where to buy Sarepta Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you determine where to buy Sarepta Therapeutics stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Pick your method of payment and add your information.
- Analyze Sarepta Therapeutics stock: The Sarepta Therapeutics ticker symbol is SRPT. Is Sarepta Therapeutics stock a good investment? Should you buy shares of SRPT? How do SRPT's underlying business fundamentals look? Do top analysts think Sarepta Therapeutics is a good buy? Why has SRPT's stock price moved recently? (Hint: Our stock market analysis tools can help you decide if SRPT is a good stock to buy).
- Make your SRPT trade: Decide if you will purchase SRPT shares at the current market price or use a limit order to buy SRPT shares at a given price.
- Keep tabs on your SRPT investment: Create a watchlist to the latest updates on your investment in Sarepta Therapeutics shares.
Step 1: Decide where to buy Sarepta Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy SRPT shares.
Our preferred brokerage: eToro
In our opinion, eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world markets: From Tech to Utilities, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal information so you are able to invest in SRPT today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to create your new trading account.
- Submit your info by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've opened your account on the best stock broker app, your next step is to transfer the money for your investment:
Watch the walkthrough below for more details transferring money into your investment account.
Step 4: Analyze Sarepta Therapeutics stock
Once you have figured out the best place to buy Sarepta Therapeutics stock, it's very important to evaluate their stock prior to investing, so you can wrap your head around the risk as well as the opportunity.
Overview of key SRPT info
Sarepta Therapeutics Due Diligence Checks
WallStreetZen was created to help everyday investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on SRPT's stock page.
What is the fair value of SRPT stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge SRPT's fair value.
Using relative valuations measures:
- SRPT could be undervalued based on its P/E ratio of 21.78x, relative to Biotechnology industry P/E ratio of -177.72x
- SRPT could be undervalued based on its P/B ratio of 3.42x, relative to Biotechnology industry P/B ratio of 4.05x
- SRPT could be undervalued based on its PEG ratio of 0.25x
You can do more valuation analysis on SRPT's stock here.
SRPT Financial Overview
Passed Financial Due Diligence Checks:
- There are more short-term assets than short-term liabilities on the SRPT balance sheet.
- There are more short-term assets than long-term liabilities on the SRPT balance sheet.
- SRPT has cash burn of 342743000. It has enough cash and short-term investments to cover this for at least one year.
- SRPT has $1.35B in cash and short term investments. This is sufficient to cover its annual cash burn of $342.74M.
- SRPT profit margin has gone up from -43.1% to 12.4% in the past year.
Failed Financial Due Diligence Checks:
- Total SRPT debt is higher than 5 years ago, relative to shareholder equity.
- SRPT has a relatively high debt to equity ratio of 1.59.
Is SRPT stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 14 Wall Street analysts who monitor SRPT, the consensus analyst rating on SRPT is a Buy
Please note that analyst forecasts are not recommendations, nor are they investment advice.
Latest SRPT Analyst Upgrades/Downgrades
Louise Chen, a bottom 4% analyst from ScotiaBank maintains SRPT with a hold rating and lowers their SRPT price target from $105.00 to $80.00, on Mar 20, 2025.
Kristen Kluska, a top 3% analyst from Cantor Fitzgerald reiterates SRPT with a strong buy rating and maintains their SRPT price target from $163.00 to $163.00, on Mar 19, 2025.
David Hoang, a top 45% analyst from Deutsche Bank maintains SRPT with a hold rating and lowers their SRPT price target from $124.00 to $99.00, on Mar 19, 2025.
Raghuram Selvaraju, a bottom 1% analyst from HC Wainwright & Co. reiterates SRPT with a sell rating and maintains their SRPT price target from $75.00 to $75.00, on Jan 30, 2025.
Biren Amin, a bottom 4% analyst from Piper Sandler maintains SRPT with a strong buy rating and lowers their SRPT price target from $200.00 to $182.00, on Nov 27, 2024.
Piper Sandler's Biren Amin lowered their price target on Sarepta Therapeutics (NASDAQ: SRPT) by 9% from $200 to $182 on 2024/11/27. The analyst maintained their Strong Buy rating on the stock.
Amin said their price target hike was catalyzed by the 2024/11/26 announcement that Sarepta Therapeutics has entered into a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical siRNA* programs/multiple TRiM programs for $500M cash upfront, $325M equity investment, $250M to be paid over 5 years, up to $10B in total milestones, plus low double-digit royalties.
Footnotes
'* From here: Small interfering RNA (siRNA) is a class of double-stranded non-coding RNA molecules, typically 20–24 base pairs in length, similar to microRNA (miRNA), and operating within the RNA interference (RNAi) pathway. siRNA interferes with the expression of specific genes with complementary nucleotide sequences by degrading messenger RNA (mRNA) after transcription, preventing translation. Since, in principle, any gene can be knocked down by a synthetic siRNA with a complementary sequence, siRNAs are an important tool for validating gene function and drug targeting in the post-genomic era.
You can dig deeper into what analysts are forecasting on the Sarepta Therapeutics stock forecast page.
SRPT Momentum
SRPT Revenue
Last year, SRPT revenue was $1.90B. During the past five year, SRPT's revenue has increased by 37.94% per year. This was slower than the Biotechnology industry average of 44.43%.
Find out more about SRPT's earnings and revenue performance here.
What are SRPT insiders up to?
In the past 12 months, insiders at SRPT have sold more shares than they have bought.
Claude Nicaise, Director of SRPT, was the latest SRPT insider to buy. They bought $245,404.28 worth of SRPT stock on Mar 12, 2025.
Research more about who owns SRPT stock here.
Can I rely on SRPT as an income stream?
No, Sarepta Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your SRPT trade
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly the best for newer investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a particular price, use a limit order.
Click the Open Trade button and your broker will execute your order.
If you need more info about investing in stocks on eToro, click the how to video below:
Step 6: Keep tabs on your SRPT investment
Now that you own some SRPT stock, you'll want to keep up with your company.
Add SRPT to a watchlist to keep tabs on your SRPT stock.
SRPT Feed
How to Buy Stock in Sarepta Therapeutics
To summarize, here are the 6 steps you need to take to buy Sarepta Therapeutics stock right now:
- Decide where to buy Sarepta Therapeutics stock
- Open a brokerage account
- Deposit funds into your investment account
- Analyze Sarepta Therapeutics stock
- Make your SRPT trade
- Keep tabs on your SRPT investment
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get notifications regarding your new investment in Sarepta Therapeutics, add SRPT to your watchlist by clicking the button below.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.